argenx stock
ARGXNASDAQargenx SE, HealthcareISIN US04016X1019
70Score 70 out of 100, Strong
Price and trend
81 / 100
Price history
+10% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 73).
The price is 7.3% below its 52-week high. Largest decline in 9 years: 38% (July 2023 to December 2023).
Chart figures for advanced users
- SMA 50$925.75
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$859.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$663.93
- The lowest closing price of the last twelve months.
- Resistance$1,058.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- argenx SE belongs to the Biotechnology industry (Netherlands) and, with a market value of $61.49B, is number 5 of 296 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $4.15B (up 89.6% year on year) and earnings of $1.29B (up 55.1%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 132 of 714 in Healthcare, median 53.
- The P/E is 33.5 (Biotechnology median 21.3, own median of recent years 42).
- Our model puts fair value at $692.47, with the price 41% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 151.5% a year since 2020, Biotechnology median 19.7%.Growth 70
- High return on capitalReturn on invested capital 41.2% in fiscal 2025, Biotechnology median −24.3%.Profitability 93
- More cash than debtCash $5.18B, financial debt $47M.Stability 88
Weaknesses
- DilutionShare count up 35% since 2020.Capital allocation 54
Its standout strengths are profitability and stability, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $532.67 and expensive above $989.24 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $761.70 (cash-flow model) and $623.24 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9%. At 10% the fair value would be $621.02, at 8% it would be $799.35.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 89.6% on the prior year. Revenue has grown strongly since 2011, at around 77% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 89%, operating 25%, net 31%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 30 Jul 2026above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- 28.4−3.2%
- Revenue
- $6.37B+2.7%
- Earnings per share
- 37.25−4.5%
- Revenue
- $8.03B+4.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at argenx
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vertex PharmaceuticalsVRTX $138.69B76
- ModernaMRNA $100.63B48
- Regeneron PharmaceuticalsREGN $99.23B81
- UCBUCB.BR $61.8B78
- Lonza GroupLONN.SW $55.85B63
- Samsung Biologics207940.KS $49.8B68
- BeOne MedicinesONC $44.88B70
- Revolution MedicinesRVMD $39.08B43
ETFs that hold argenx
Held by 123 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 4.99% | 0.89% | €11.61M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 2.87% | 0.18% | €653.55M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 2.86% | 0.18% | €954.9M |
Show 5 more
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 2.74% | 0.46% | €729.65M |
| L&G Pharma Breakthrough UCITS ETFETLI | 2.19% | 0.49% | €26.29M |
| Deka Euro Prime ESG UCITS ETFELFB | 1.83% | 0.40% | €670.04M |
| iShares Euro Total Market Growth Large UCITS ETFIQQG | 1.79% | 0.40% | €289.87M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.60% | 0.35% | €1.21B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.